NewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo®
RegulatorypositiveUbeslo®Evlarco®Positive
AI Analysis
Summary
NewAmsterdam Pharma and Menarini Group received a positive CHMP opinion recommending marketing authorization for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimiba combination). The favorable recommendation supports potential European regulatory approval.
Outcome Details
CHMP issued a positive opinion recommending marketing authorization for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib and ezetimiba fixed-dose combination)
Importance:8/10
Sentiment:
0.85
CHMPregulatory approvalEuropean Commissionobicetrapibcardiovascular
Related Companies
Read the original article
Published by PR Newswire Biotech on July 24, 2026 4:57 PM